Cancer and Blood Diseases Institute

Our Innovation, Scope Set Us Apart

The Cancer and Blood Diseases Institute at Cincinnati Children’s closely integrates patient care and research to advance knowledge and improve outcomes for our patients. We are known for offering the most advanced therapies − some of which were originally developed in our institute by nationally recognized specialists.

We are also one of the nation’s largest referral centers. Each year, experts at the Cancer and Blood Diseases Institute care for about 3,500 children and adolescents. Last year, we had more than 15,000 outpatient visits and more than 1,300 inpatient admissions, and performed more than 100 blood and marrow transplants.

What Sets Us Apart

• We are ranked among the top four institutions for pediatric cancer care nationally by U.S. News & World Report.
  
• We have one of the largest pediatric blood and marrow transplantation programs in the United States. Our program has performed more than 1,300 transplants in our 20-year history. Currently we perform transplants on more than 100 children a year with a 96 percent survival rate, much higher than the national average.
  
• We were the first to use bone marrow transplant to cure genetic disorders such as autoimmune
  lymphoproliferative syndrome (ALPS). Such innovations have paved the way for further research and refinement of many blood and marrow transplant techniques.
  
• Our oncologists are national leaders in the development of cutting-edge treatment for rare, relapsed and high-risk cancers. We are one of the nation’s largest centers for innovative cancer therapies.
  
• Our Immune Deficiencies and Histiocytosis Program is nationally recognized as one of the best; 90 percent of our patients travel from outside of Ohio to receive care here.
  
• We have one of the largest Fanconi anemia comprehensive care centers in the world and the first of its kind in the nation. We currently provide care for more than 130 patients with this rare disease − a significant portion of all patients with this disease in the world.
  
• We offer extensive services for newborns with sickle cell anemia. In fact, Cincinnati Children’s was one of the first hospitals to test newborns for sickle cell anemia, starting in the late 1970s.
  
• Our experts in sickle cell disease have pioneered treatments that have become standard of care. We pioneered the use of prophylactic penicillin for newborns to guard against infection, the use of incentive spirometry to prevent acute chest syndrome, and we preformed the first blood and marrow transplant for sickle cell anemia in the United States.
  
• We are a major referral center for complex and rare hemangiomas, vascular tumors and malformations − currently following 2,000 patients, with 450 new patients seen in a single year.
  
• We are the only center to offer clinical trials using new drugs to treat complex vascular anomalies.